US5175166A - Muscarinic agonists - Google Patents

Muscarinic agonists Download PDF

Info

Publication number
US5175166A
US5175166A US07/750,504 US75050491A US5175166A US 5175166 A US5175166 A US 5175166A US 75050491 A US75050491 A US 75050491A US 5175166 A US5175166 A US 5175166A
Authority
US
United States
Prior art keywords
compound
salt
tetrahydropyrimidine
methoxycarbonyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/750,504
Other languages
English (en)
Inventor
Philip G. Dunbar
Graham J. Durant
Wayne P. Hoss
William S. Messer, Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toledo
Original Assignee
University of Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toledo filed Critical University of Toledo
Priority to US07/750,504 priority Critical patent/US5175166A/en
Assigned to UNIVERSITY OF TOLEDO, THE reassignment UNIVERSITY OF TOLEDO, THE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: DURANT, GRAHAM J.
Assigned to UNIVERSITY OF TOLEDO, THE reassignment UNIVERSITY OF TOLEDO, THE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: DUNBAR, PHILIP G.
Assigned to UNIVERSITY OF TOLEDO, THE reassignment UNIVERSITY OF TOLEDO, THE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: MESSER, WILLIAM S., JR.
Assigned to UNIVERSITY OF TOLEDO, THE reassignment UNIVERSITY OF TOLEDO, THE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: HOSS, WAYNE P.
Priority to PCT/US1992/006842 priority patent/WO1993003726A1/en
Priority to EP92919345A priority patent/EP0630244B1/de
Priority to AT92919345T priority patent/ATE187070T1/de
Priority to ES92919345T priority patent/ES2138977T3/es
Priority to CA002113424A priority patent/CA2113424C/en
Priority to DE69230378T priority patent/DE69230378T2/de
Priority to JP50446393A priority patent/JP3411276B2/ja
Publication of US5175166A publication Critical patent/US5175166A/en
Application granted granted Critical
Priority to US08/224,271 priority patent/US5403845A/en
Priority to JP2001175844A priority patent/JP3519062B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to drugs and more specifically the invention relates to heterocyclic drug compositions containing carbon and nitrogen atoms in the ring. Even yet more specifically the present invention relates to substituted 1,4,5,6-tetrahydropyrimidine compositions, substituted 1,2,3,6-tetrahydropyrimidine compositions, and substituted 3,4,5,6-tetrahydropyridine compositions.
  • the invention also relates to treating mammals with such compositions. Further, the invention also relates to pharmaceutical preparations comprising such compositions and a suitable carrier.
  • the neurotransmitter acetylcholine mediates a variety of responses within the central nervous system and plays an important role in memory function and cognition. Cholinergic responses are mediated by muscarinic and nicotinic receptors throughout the brain, although it is accepted generally that receptors in the cerebral cortex and hippocampus are associated with memory and cognitive function. Agents that block acetylcholine activity at muscarinic receptors and lesions of cholinergic projections to the cortex and hippocampus impair memory and cognition.
  • the nucleus basalis of Meynert is the source of acetylcholine for the cerebral cortex and hippocampus.
  • the cholinergic cells within the basal nucleus degenerate in Alzheimer's disease, a disorder that is associated with memory dysfunction and progressive cognitive decline.
  • Current therapeutic approaches for Alzheimer's disease include treatment with agents that increase levels of acetylcholine or mimic the effects of acetylcholine at receptors.
  • acetylcholinesterase the enzyme that metabolizes acetylcholine.
  • the first approach using either choline or phosphatidylcholine, has not been very successful although acetylcholinesterase inhibitors have shown some therapeutic efficacy.
  • Clinical trials with these compounds have documented some improvements in cognitive function and ability to conduct daily tasks.
  • Major drawbacks with AChEase inhibitors include toxicity and the side effects associated with activation of receptors in the peripheral nervous system.
  • M 1 antagonists such as pirenzepine
  • an M 1 selective muscarinic agonist with high central nervous system activity is provided.
  • therapeutic benefits are provided by providing improved compositions which stimulate muscarinic receptors.
  • A is H or NHR
  • R is H, an alkyl of 1-8 carbon atoms, preferably 1-4, and most desirably, 1-3 carbon atoms, --C(O)--R 1 or --C(O)OR 1
  • Z is --C(O)OR 1 , or --OC(O)R 1 , or ##STR2## wherein X is O or S, and wherein R 1 is a monovalent hydrocarbon radical having 1-8 carbon atoms, preferably 1-4, and most desirably, 1-3 carbon atoms
  • R 2 is alkyl of 1-8 carbon atoms, preferably 1-4, and most desirably, 1-3 carbon atoms, alkylthioalkyl of up to 8, preferably up to 3 or 4, carbon atoms, alkoxyalkyl of up to 8, preferably up to
  • R 4 and R 5 will contain 1-4 carbon atoms, preferably 1-3.
  • the monovalent hydrocarbon radical may, for example, be an alkyl, an alkaryl, an aryl, an aralkyl, an alkenyl or alkynyl radical.
  • Exemplary of highly desirable inventive compounds, and their pharmaceutically acceptable salts are: 5-methoxycarbonyl-1,4,5,6-tetrahydropyrimidine; -acetoxy-1,4,5,6-tetrahydropyrimidine; 1-methyl-5-methoxycarbonyl-1,2,3,6-tetrahydropyrimidine; 2-amino-5-methoxycarbonyl-3,4,5,6-tetrahydropyridine; 5-ethoxycarbonyl-1,4,5,6-tetrahydropyrimidine; propynyl 1,4,5,6-tetrahydropyrimidine-5-carboxylate; 5(3-methyl-1,2,4-oxadiazol-5-yl)-1,4,5,6 tetrahydropyrimidine.
  • Z is moiety I, II, III, IV, and VI, especially I, for example, with structure (i) as a nucleus.
  • the present invention provides an improvement in methods for providing a therapeutic benefit to mammals, for example, those having a cholinergic deficit comprising administering to such mammal, in any convenient manner, a non-toxic amount, but an amount effective to stimulate muscarinic receptors, of a compound as described above, or a pharmaceutically acceptable salt thereof.
  • compositions which include amounts effective to stimulate cognitive function of a compound as described above, or pharmaceutically acceptable salt thereof, along with a pharmaceutically acceptable solid or liquid carrier.
  • acids for the formation of pharmaceutically acceptable acid addition salts are hydrochloric, sulfuric, phosphoric, acetic, trifluoro acetic, benzoic, citric, malonic, salicylic, malic, fumaric, oxalic, succinic, tartaric, lactic, gluconic, ascorbic, maleic, aspartic, benzenesulfonic, methane and ethanesulfonic, hydroxymethane and hydroxyethanesulfonic acids and the like. Further particulars can be had by reference to the Journal of Pharmaceutical Science, 66 (1) 1-19 (1977).
  • the compounds utilized in the pharmaceutical method of this invention are desirably administered to the patient in amounts effective to stimulate muscarinic receptors and thereby stimulate central and/or peripheral nervous systems. Since the compounds of this invention will stimulate central muscarinic acetylchloline receptors they are useful when administered in effective amounts, to treat not only presenile and senile dementia but also Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette syndrome. In effective amounts, they are also useful as analgesics, for example, in treating painful conditions like rheumatism, arthritis and terminal illness and they are useful in the peripheral nervous system to treat glaucoma and atonic bladder conditions.
  • the effective amounts vary but usually translate to dosage levels of from about 0.7 to about 7000 mg per day. For a normal human adult of approximately 70 kg of body weight this translates into a dosage of about from 0.01 to 100 mg/kg of body weight per day.
  • the specific dosages employed may vary depending upon the requirements of the patient, the severity of the condition being treated and the activity of the compound being employed. The determination, however, of optimum dosages for any particular situation is well within the skill of the art.
  • compositions of the compounds (or their pharmaceutically acceptable salts) of this invention inert, solid or liquid pharmaceutically acceptable carriers will be employed.
  • Solid form preparations include powders, tablets, dispersable granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted, and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
  • Powders and tablets preferably contain between about 5 to about 70% by weight of the active ingredient.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • preparation is intended to comprehend within its scope a formulation of the active compound with encapsulating material as a carrier, thereby providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier and is thus in association with it.
  • cachets are also included.
  • Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
  • Liquid form preparations include solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration.
  • Sterile water solutions of the active component or sterile solutions of the active component in solvents comprising water, ethanol, or propylene glycol are mentioned as examples of liquid preparations suitable for parenteral administration.
  • Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.
  • Aqueous solutions for oral administration can be prepared by dissolving the active compound in water and adding suitable flavorants, coloring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, or other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is divided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself.
  • alkyl, alkoxy and alkylthio groups from which the various R substituents on structures (i), (ii) and (iii) will be selected in forming compounds of the present invention are methyl, ethyl, propyl, butyl and its various isomers, methoxy, ethoxy, propoxy, hexoxy as well as, for example, methyl, ethyl and propylthio groups.
  • aryl, alkaryl, aralkyl, alkenyl and alkynyl groups from which R 1 may be selected on those structures are phenyl (aryl), methylphenyl (alkaryl), phenylmethyl (aralkyl), ethenyl and propenyl (alkenyl) as well as ethynyl and propynyl, i.e. propargyl (alkynyl).
  • alkylthioalkyl radicals are methylthioethyl and ethylthiopropyl whereas methoxypropyl and ethoxymethyl are representative of alkoxyalkyl radicals.
  • R 1 hydrocarbon radical be an alkyl radical of one or two carbon atoms.
  • the hydrocarbon radical will not be propyl, isopropyl or benzyl.
  • muscarinic agonist having high central nervous system activity as contemplated by the present invention and which will selectively bind to M 1 muscarinic receptors and stimulate phosophoinositide metabolism in the brain are those of the above with the following structures: (ii) and wherein R is CH 3 and Z is C(O)OCH 3 , that is, 1-methyl-5-methoxycarbonyl-1,2,3,6-tetrahydropyrimidine; (i) wherein R is H, Z is OC(O)CH 3 and wherein A is H, that is, 5-acetoxy-1,4,5,6-tetrahydropyrimidine; (iii) wherein R is H and wherein D at the 5 position is C(O)OCH 3 and wherein D at the 6 position is H, that is, 2-amino-5-methoxycarbonyl-3,4,5,6-tetrahydropyridine; (i) wherein A is H, R is H and Z is --C(O)OCH 3 ,
  • Schematic sequence I (a) and (b) illustrate the production of compounds of structures (i) and (iii) above.
  • a properly substituted pyridine or pyrimidine is catalytically reduced to the tetrahydro derivative and then alkylated to those structures.
  • compounds of structure (ii) are produced by the schematic sequence II (a) and (b). This sequence first involves an alkylation to produce a quaternary compound which then is subjected to a sodium borohydride reduction to produce a desired structure.
  • alkylation or dealkylation
  • alkylation is used not only to refer to the introduction (or removal) of an alkyl radical into a molecule but also the introduction (and removal) of other monovalent hydrocarbon radicals, e.g. alkaryl, aryl, araalkyl, alkenyl etc., into a molecule.
  • compounds of structure (ii) will be formed by first of all reacting the substituted pyrimidine with an acyl oxamine followed by alkylation (IV a) to form the quaternary compound which is subjected to sodium borohydride reduction (IV b) to produce structure (ii).
  • Reaction sequence V a,b,c produces compounds of structure (i) by starting with a hydroxy diamino propane.
  • the hydroxy diamino propane is first subjected to a condensation reaction (V a) with a formate or carbamate and the reaction product is esterified with an organic acid (V b).
  • the 1,4,5,6-tetrahydropyrimidine ester is then subjected to alkylation (V c) to produce compounds (i).
  • Structures (i) and (iii) are produced by reaction sequences VIII, XII, XIII and XIV.
  • reaction sequence VIII a properly substituted bromo pyridine or pyrimidine is subjected to halogen--metal exchange followed by carboxylation and esterification to produce the pyridine or pyrimidine ester.
  • the ester (sequence XII) is then subjected to catalytic reduction followed by alkylation (XIII) to produce a protected tetrahydro ester.
  • Structures (i) and (iii) are produced from that ester by sequence XIV.
  • Sequence XIV shows a procedure, in which a properly substituted amidoxime, or a hydroxy guanidine (or sulphur analogs thereof), is reacted, under basic catalysis (sodium hydride), with the protected tetrahydro ester to produce the (i) or (iii) structures.
  • Sequence XV shows the deprotection or dealkylation of the products of sequence XIV to produce compound structures (i) when Y is NR', R' is trityl or C(O)OR (with R being a monovalent hydrocarbon of 1-7 carbon atoms) in such products.
  • Chemical structures (i) and (iii) can be formed in accordance with reaction sequence VI and VII.
  • the brominated pyridine or pyrimidine is first subjected to halogen-metal exchange and carboxylation followed by catalytic reduction (VI) to produce the acid.
  • This acid is then esterified (VII) in the presence of thionylchloride and then alkylated to produce compounds (i) and (iii).
  • Structure (ii) can be produced by reaction sequences VIII, IX and X.
  • reaction sequence VIII is used to form the pyridine or pyrimidine ester. This ester is then subjected to alkylation (IX) to form a quaternary compound and this quaternary compound is then reduced (X) to compounds of structure (ii).
  • Steps VIII, XI and XVII can also be employed to produce compounds of structure (ii).
  • the pyrimidine ester of step VIII is, under basic catalysis (NaH), reacted with a properly substituted amidoxime or hydroxyguanidine (or sulphur analog thereof), as indicated in step XI, to form a pyrimidine having oxadiazole or thiadiazole substitution. That substituted pyrimidine is then (step XVII) subjected to quaternization and borohydride reduction to produce compounds of structure (ii).
  • reaction sequence XXXIV pyrimidine aldehydes are converted to oxathiolanes or dioxolanes by a process which involves dehydration using a properly substituted glycol or a thiol followed by quaternization and then sodium borohydride reduction.
  • step XXXV Compounds (i) or (iii) are sequentially produced (step XXXV) by catalytic reduction of the pyridine or pyrimidine aldehyde and alkylation to produce the 3,4,5,6-tetrahydropyridine or the 1,4,5,6- tetrahydropyrimidine structure.
  • the tetrahydropyridine or the tetrahydropyrimidine compositions are then subjected to dehydration with a properly substituted glycol or thiol (step XXXVI) to produce compounds (i) and (iii).
  • Compounds (i) and (iii) can also be produced by the reaction sequence of steps XIX, XXI, and XXIV and compounds of structure (i) can also be produced by sequence XIX, XX, XXII and XXV.
  • Compounds of structure (ii) can be produced by reaction sequence XIX, XXI and XXIII. The initial reaction in forming these compounds is a Strecker synthesis (XIX) to form the amino nitrile intermediate.
  • sequence XXI the amino nitrile compound is subjected to cyclization using sulfur monochloride to produce a halo thiadiazole alkylating agent.
  • this alkylating agent is then reacted with a metal alkyl, or with a compound having an alkoxy or alkylthio anion, followed by quaternization and sodium borohydride reduction to produce a thiadiazole of structure (ii).
  • the halo thiadiazole alkylating agent of step XXI is reacted (step XXIV) with a metal alkyl, or, for example, with an alkoxy or alkylthio anion followed by catalytic reduction and, alkylation to form thiadiazole compounds of structure (i) and (iii).
  • sequence XIX the aminonitrile compound resulting from the Strecker synthesis
  • sequence XXII the aminonitrile is hydrolized, with the product then being subjected to catalytic reduction and alkylation to produce a protected pyrimidine amide.
  • This protected pyrimidine is then subjected to cyclization (XXII) employing sulfur monochloride, or thionylaniline, to produce a hydroxy thiadiazole substituent on a 1,4,5,6-tetrahydropyrimidine nucleus.
  • compounds of formula (i) are formed when R' is C(O)OR or trityl in the product of step XXII in accordance with step XXV by alkylation and deprotection.
  • compounds of structure (ii) can be formed by reaction sequences XXVII, XXVIII and XXX. From a properly substituted cyano methyl pyridine or pyrimidine compound, structures (i) and (iii) can be formed by reaction sequences XXVII, XXVIII and XXXI. Compounds of structure (i) can also be formed by reaction sequence XXVII, XXXVII, XXIX and XXXII.
  • reaction sequence XXVII the substituted pyridine or pyrimidine compound is subjected to a base catalyzed reaction with a methylnitrite to form a cyano oxime.
  • the cyano oxime is then reacted (sequence XXVIII) with hydroxylamine and then cyclized using phosphorous pentachloride and the cyclized product is then subjected to diazotization and then chlorination to produce an alkylating halooxadiazole substituted halo pyridine or pyrimidine compound.
  • reaction sequence XXX the pyrimidine compound is reacted with a metal alkyl or with an MX'R compound and then subjected to quaternization followed by sodium borohydride reduction to produce compounds of structure (ii).
  • the step XXVIII compound is used to form compounds of structure (i) or (iii) in accordance with reaction sequence XXXI by first of all reacting with an R" M compound followed by catalytic reduction and then alkylation when Y is N. It can be observed in the reaction sequences that by dealkylation, or deprotection, compounds produced in accordance with reaction sequence XXXI, when Y is NR' and R' is C(O)OR or trityl, can be converted to compounds of structure (i) as illustrated in reaction sequence XXXIII.
  • reaction sequence XXVII can also be converted, through reaction sequences XXXVII, XXIX and XXXII, to compounds of structure (i).
  • reaction sequence XXXVII the cyano oxime is reacted with hydroxylamine and then subjected to catalytic reduction followed by alkylation to form the properly protected amino oxime.
  • reaction sequence XXIX is subjected to cyclization, using phosphorous pentachloride, and then subjected to diazotization and chlorination to form an alkylated, chlorooxadiazole substituted, tetrahydropyrimidine structure which is then employed as an alkylating agent in reaction sequence step XXXII to react with an R" M compound followed by deprotection with TFA to produce structure (i).
  • 1,4,5,6-Tetrahydropyrimidine-5-carboxylic acid hydrochloride (1.5 g, 9.12 mmol) was dissolved in absolute ethanol (40 ml) by heating. The thionyl chloride (1.1 g, 9.16 mmol) was added dropwise with stirring. The resulting solution was refluxed 20 h and then evaporated to dryness in vacuo. The residue was taken up in absolute methanol (5 ml) and dry THF (10 ml) was added to induce crystallization, giving 1.1 g (63%) product as white crystals, mp 125°-127° C. 300 MHz nmr confirmed the product. Microanalysis calc.: C 43.64, H 6.75, N 14.55; found: C, 43.43, H 6.58, N 14.40.
  • 1,4,5,6-Tetrahydropyrimidine-5-carboxylic acid hydrochloride (1.5 g, 9.1 mmol) was dissolved in 1-propanol (30 ml). To the mixture was added thionyl chloride (1.1 g, 9.1 mmol) and the solution was refluxed for 22 h. The solvent was evaporated in vacuo to dryness. The residue was crystallized from methanol/THF to give 1.06 g (56%) of white crystals, mp 128°-130° C. 300 MHz nmr indicated product. Microanalysis calc.: C 46.49, H 7.26, N 13.56, found: C 46.21, H 6.96, N 17.41.
  • 1,4,5,6-Tetrahydropyrimidine-5-carboxylic acid hydrochloride (1.0 g, 6.08 mmol) was suspended in 2-propanol (50 ml) and thionyl chloride (0.76 g, 6.39 mmol) was added dropwise. The resulting mixture was refluxed 24 h. The pink solution was treated with charcoal and then reduced in volume to 15 ml by evaporating unreacted alcohol. By allowing the solution to stand overnight, white crystals (1.08 g, 84%) were obtained in three crops, mp 170° C. 300 MHz nmr confirmed product. Microanalysis calc.: C 46.49, H 7.26, N 13.56, found: C 46.49, H 7.25, N 13.64.
  • 1,4,5,6-Tetrahydropyrimidine-5-carboxylic acid hydrochloride (1.0 g, 6.1 mmol) was suspended in dry benzyl alcohol (20 ml). To the mixture was added thionyl chloride (0.76 g, 6.39 mmol) and the resulting mixture was heated in an oil bath at 80° C. for 24 h. The clear solution was poured to anhydrous ethyl ether (100 ml) to induce precipitation. The white solids were collected and crystallized from methanol/THF to give 1.18 g (76%) of product (mp 113°-114° C.). 300 MHz nmr indicated the product. Microanalysis calc.: C 56.58, H 5.89, N 11.00; found: C 56.34, H 6.03, N 11.19.
  • 1,4,5,6-Tetrahydropyrimidine-5-carboxylic acid hydrochloride (2.22 g, 13.5 mmol) was suspended in oxalyl chloride (30 ml). The mixture was refluxed for 6 h with stirring and then unreacted oxalyl chloride was evaporated to dryness. To the residue was added propargyl alcohol (20 ml) and the resulting mixture was stirred for 10 h at room temperature. The mixture was evaporated in vacuo to dryness. The residue was recrystallized from methanol/THF to give white crystals --400 mg (14%), mp 127°-129° C. Microanalysis calc.: C 45.40, H 5.67, N 13.23; found: C 45.55, H 5.70, N 13.18.
  • 1,4,5,6-Tetrahydropyrimidine-5-carboxylic acid hydrochloride (6.34 g, 38.5 mmol) was dissolved in anhydrous methanol (200 ml) with stirring, and thionyl chloride (2.74 ml, 38.5 mmol) was added dropwise. The resulting solution was refluxed with stirring for 18 hours, then evaporated in vacuo to white solids. The crude product was recrystallized from anhydrous methanol to yield 4.12 g (60%) white crystals, mp 160°-164° C. Calculated: C 40.34, H 6.21, N 15.69; found: C 40.17, H 6.41, N 15.73.
  • 1,4,5,6-Tetrahydro-5-methoxycarbonylpyrimidine hydrochloride 300 mg, 1.35 mmol
  • NaH 60% in mineral oil 107 mg, 1.35 mmol
  • anhydrous DMF 5 ml
  • CH 3 I 84 ⁇ l, 1.35 mmol was added via syringe and stirring continued 3 hours at room temperature.
  • the solvents were evaporated in vacuo and the residue triturated with chloroform.
  • 1,4,5,6-Tetrahydro-5-methoxycarbonylpyrimidine hydrochloride (I.49 g, 8.3 mmol), 1,8 diazabicyclo [5.4.0] undec-7ene, (hereinafter diazabicycloundecene and/or DBU), (2.5 mL, 16.6 mmol), and tritylchloride (2.32 g, 8.3 mmol) were suspended in anhydrous DMF (20 ml) with stirring under nitrogen at room temperature.
  • the hydrochloride salt was obtained by addition of 1M HCl in ether to an ethanol solution of the resin, evaporation of solvents and recrystallization (ethanol/ether) to yield 35 mg (15%) yellow crystals mp 160°-162° C.. Calculated: C 43.64, H 6.80, N 14.54; found: C 43.55, H 6.65, N 14.40.
  • 6-Aminonicotinic acid (1.06 g, 7.7 mmol) was suspended with stirring in anhydrous methanol (50 ml), and thionyl chloride (0.55 ml, 7.7 mmol) was added dropwise. The suspension was refluxed to a clear solution over 15 hours. The solvent was evaporated in vacuo and the residue taken up in water (20 ml). The solution was raised to pH 9 (sat. Na 2 CO 3 ), extracted with chloroform, and dried over MgSO 4 . Evaporation of the chloroform gave 1.23 g (100%) product as white
  • 1,3-Diamino-2-hydroxypropane (10 g, 111 mmol) and ethyltrifluoroacetate (13.5 ml, 114 mmol) were dissolved in xylene (85 ml) and refluxed overnight in a Dean-Stark apparatus. The solvents were evaporated in vacuo to give a dark viscous oil 21 g identified by 300 MHz nmr as product.
  • Methyliodide 38 ⁇ l, 0.6 mmol was added to a stirred solution of 1-triphenylmethyl-5(3-methyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine (250 mg, 0.6 mmol) in chloroform (lml), in a round bottom flask with a septum, at room temperature. After 12 hours stirring the solvents were evaporated in vacuo giving 330 mg (100%) crude white crystals identified by 300 MHz nmr.
  • Methyliodide (47 ⁇ l, 0.6 mmol) is added to a stirred solution of 1-triphenylmethyl-5-methoxycarbonyl-1,4,5,6-tetrahydropyrimidine (288 mg, 0.75 mmol) in chloroform (5 ml), in a round bottom flask with a septum, at room temperature. After 12 hours stirring the solvents are evaporated in vacuo giving 395 mg (100%) white crystals identified by 300 MHz nmr.
  • Potassium cyanide (651 mg, 10 mmol) and ammonium chloride (588 mg, 11 mmol) are dissolved in water (2.6 mL) with stirring.
  • Pyrimidine-5-carboxaldehyde (1.08 g, 10 mmol) in methanol (2.6 mL) is added to the clear solution rapidly, giving first a yellow, then a dark red solution, and mildly exothermic reaction.
  • Amino(pyrimidin-5-yl)acetamide (950 mg, 6.7 mmol) is suspended in a mixture of 50 ml water and concentrated hydrochloric acid (13.3 mmol). The mixture is hydrogenated at 26 psig over 300 mg Pd-on-carbon 10% in a Parr hydrogenator for 3 h. Then the suspension is filtered and the filter rinsed twice with hot water (20 ml). The filtrate can be evaorated in vacuo to give 1.41 g yellow oil (92%). The oil is crystallized from anhydrous methanol/THF to give 1.33 g (87%) white crystals, identified by 300 MHz nmr.
  • N-Thionylaniline (2.6 mL, 23.2 mmol) is added to amino(1-triphenylmethyl-1,4,5,6-tetrahydropyrimidin-5-yl)acetamide (1.64 g, 4.1 mmol) suspended in pyridine (25 ml). After heating at 90° C. for 48 hours the pyridine is evaporated, and the black residue partitioned between chloroform and water.
  • the biological activity of representative compounds of the present invention was demonstrated using a number of tests. These tests included using 3 H-1-quinuclidinyl benzilate (QNB), 3 H-pirenzepine (PZ), 3 H-oxotremorine M (OXO-M) to evaluate the effectiveness of the compounds for binding to muscarinic receptors.
  • QNB 3 H-1-quinuclidinyl benzilate
  • PZ 3 H-pirenzepine
  • OXO-M 3 H-oxotremorine M
  • the potency and efficacy of the compounds and their salts as selective M 1 agonists were evaluated by measuring phosphoinositide (PI) turnover in the cortex, PI turnover in the hippocampus. Further details of the testing methods are set forth immediately below.
  • Binding was carried out essentially as described previously [Farrar, J.R. Hoss, W., Herndon, R.M. and Kuzmiak, M. Characterization of Muscarinic Cholinergic Receptors in the Brains of Copper-Deficient Rats, J. Neurosci 5:1083-1089, 1985.] Binding was determined indirectly by the ability of compounds to compete with 50 pM [ 3 H]-1-quinuclidinyl benzilate ([ 3 H]-QNB) in a suspension of brain membranes.
  • Each sample contained approximately 10 pM receptors (2-4 ⁇ g/ml of protein) in 40 mM sodium/potassium phosphate buffer, pH 7.4 and varying concentrations of compound in a final volume of 10 ml. Samples were incubated for 2.0 hr. at room temperature and then filtered through glass fiber filters using a Brandell cell harvester adapted for receptor binding work and the filters washed twice with two 5-ml portions of cold buffer. Nonspecific binding was evaluated by the inclusion of excess atropine in a separate set of samples. IC 50 values were determined from Hill plots of the inhibition data and are reported as means of three independent experiments each performed in triplicate.
  • binding was determined indirectly by the ability of compounds to compete with 1 nM 3 H-pirenzepine ( 3 H--PZ), or 3 nM 3 H-oxotremorine M ( 3 H--OXO--M) in a suspension of brain membranes.
  • 3 H--PZ 3 nM 3 H-pirenzepine
  • 3 H--OXO--M 3 nM 3 H-oxotremorine M
  • Each sample contained approximately 0.1 mg/ml protein for 3 H--OXO--M in 20 mM Tris-Cl buffer with 1 mM MnCl 2 and varying concentrations of compound in a final volume of 10 ml. Samples were incubated 1 hr.
  • Rats were killed by cervical dislocation and their brains rapidly removed. Tissue was homogenized in 9 vol. (w/v) of a 40 mM sodium-potassium phosphate buffer solution (pH 7.4) buffer solution with a Brinkman Polytron homogenizer five times for 10 sec at 5 sec intervals. The crude homogenate was subjected to centrifugation for 10 min at 1000 ⁇ g, the supernatant saved, and the pellet resuspended in 9 vol. (w/v) of homogenization buffer and spun for another 10 min at 1000 ⁇ g. The supernatants were combined and spun again for 30 min at 17,500 ⁇ g. The resultant pellet was resuspended by homogenization in a Teflon-glass homogenizer in 10 vol.
  • Brain slices (300 ⁇ 300 ⁇ m) were prepared using a McIlwain tissue chopper and dispersed in Krebs-Hensleit buffer (KHB) containing 118 mM NaCl, 4.7 mM KCl, 1.3 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 25 mM NaHCO 3 , and 11.7 mM glucose equilibrated with 95% O 2 /5% CO 2 to final pH of 7.4. The slices were gently agitated at 37° C. in a shaking water bath for 45 min with three changes to buffer.
  • KHB Krebs-Hensleit buffer
  • the amount of [ 3 H]-IP's formed in the assay was determined essentially according to Wreggett and Irvine (Wreggett, K.A. and Irvine, R.F., A Rapid Separation Method for Inositol Phosphates and their Isomers, Biochem. J., 245:655-660, 1987) except that the separation of inositol phosphates was carried out using an Amersham Super Separator Manifold. Briefly, ACCELL QMA anion-exchange SEP-PAK's (Waters Associates) cartridges were converted into the formate form by washing first with 10 ml of a solution of 1.0 M-ammonium formate in 0.1 M-formic acid, followed by 20 ml of distilled water.
  • Radiolabeled IP's were then eluted with 1 ml of 0.6 M-ammonium formate/0.06 M formic acid/5 mM-disodium tetraborate (pH 4.75) and 0.50 ml of this eluate was counted in 5 ml of aqueous counting scintillant. Under these conditions, carbachol produced a 3-5-fold increase in IP's accumulation over the basal unstimulated value.
  • 3 H-QNB indicates general binding to muscarinic receptors and the lower the number, the higher is the potency.
  • 3 H-PZ indicates binding to muscarinic receptors and a preference for M 1 receptors involved in memory and cognition. The lower the number for 3 H-PZ the higher the potencies; the same is true for 3 H--OXO--M which indicates agonist binding. In general, the higher the ratio of the value for 3 H--PZ to the value for 3 H--OXO--M the better is the agonistic characteristic.
  • PI Cortex measures a relevant biochemical response for muscarinic receptors linked to M 1 , M 3 , M 5 receptors and activity indicates it is an agonist at M 1 and/or M 3 and/or M 5 receptors. Higher activity numbers indicate higher efficacy relative to carbachol, a full agonist at all muscarinic receptors.
  • Phosphoinositide turnover in the hippocampus indicates a biological response in an area of the brain where M 1 receptors predominate. Higher numbers indicate greater efficacy and selectivity at M 1 receptors.
  • Phosphoinositide turnover in the hippocampus was measured on Examples 1, 9, 10, 18 and 19.
  • the values (as the above Key indicates for PI, i.e. maximal response/dosage) were: 237/1 mM (Ex. 1); 70/100 ⁇ M (Ex. 10); 704/100 ⁇ M (Ex. 9); 0/50 ⁇ M (Ex. 18); and 0/50 ⁇ M (Ex. 19).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
US07/750,504 1991-08-27 1991-08-27 Muscarinic agonists Expired - Lifetime US5175166A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US07/750,504 US5175166A (en) 1991-08-27 1991-08-27 Muscarinic agonists
JP50446393A JP3411276B2 (ja) 1991-08-27 1992-08-12 ムスカリン作用物質
DE69230378T DE69230378T2 (de) 1991-08-27 1992-08-12 Muscarinagonisten
CA002113424A CA2113424C (en) 1991-08-27 1992-08-12 Muscarinic agonists
AT92919345T ATE187070T1 (de) 1991-08-27 1992-08-12 Muscarinagonisten
EP92919345A EP0630244B1 (de) 1991-08-27 1992-08-12 Muscarinagonisten
PCT/US1992/006842 WO1993003726A1 (en) 1991-08-27 1992-08-12 Muscarinic agonists
ES92919345T ES2138977T3 (es) 1991-08-27 1992-08-12 Agonistas muscarinicos.
US08/224,271 US5403845A (en) 1991-08-27 1994-04-07 Muscarinic agonists
JP2001175844A JP3519062B2 (ja) 1991-08-27 2001-06-11 ムスカリン作用物質

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/750,504 US5175166A (en) 1991-08-27 1991-08-27 Muscarinic agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US99604992A Continuation 1991-08-27 1992-12-23

Publications (1)

Publication Number Publication Date
US5175166A true US5175166A (en) 1992-12-29

Family

ID=25018129

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/750,504 Expired - Lifetime US5175166A (en) 1991-08-27 1991-08-27 Muscarinic agonists
US08/224,271 Expired - Lifetime US5403845A (en) 1991-08-27 1994-04-07 Muscarinic agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/224,271 Expired - Lifetime US5403845A (en) 1991-08-27 1994-04-07 Muscarinic agonists

Country Status (8)

Country Link
US (2) US5175166A (de)
EP (1) EP0630244B1 (de)
JP (2) JP3411276B2 (de)
AT (1) ATE187070T1 (de)
CA (1) CA2113424C (de)
DE (1) DE69230378T2 (de)
ES (1) ES2138977T3 (de)
WO (1) WO1993003726A1 (de)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559138A (en) * 1989-02-22 1996-09-24 Novo Nordisk A/S Method of Treating Glaucoma Using Oxadiazolyl or Thiadiazolyl Tetrahydropyridines
US5618818A (en) * 1996-03-20 1997-04-08 The University Of Toledo Muscarinic agonist compounds
US5726179A (en) * 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
WO1998046232A1 (en) * 1997-04-15 1998-10-22 The University Of Toledo Muscarinic agonists
EP0897912A1 (de) * 1993-10-21 1999-02-24 G.D. Searle & Co. Amidinoderivate als NO-Synthetase-Inhibitoren
EP0874625A4 (de) * 1996-01-22 2001-03-14 Lilly Co Eli Indanderivate für antipsychotische mittel
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
KR100621192B1 (ko) 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
US20090012101A1 (en) * 2005-12-27 2009-01-08 University Of Toledo Mucarinic Agonists and Methods of Use Thereof
US20090062874A1 (en) * 2007-08-27 2009-03-05 Tracey Kevin J Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2010102218A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
CN102429909A (zh) * 2011-11-26 2012-05-02 济南环肽医药科技有限公司 一种治疗神经退行性疾病的药物
WO2012149524A1 (en) * 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9174972B2 (en) 2010-09-08 2015-11-03 Neurosolis, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10835532B2 (en) 2008-05-15 2020-11-17 The University Of Toledo Muscarinic agonists as cognitive enhancers
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11344724B2 (en) 2004-12-27 2022-05-31 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US12533531B2 (en) 2020-01-13 2026-01-27 The Feinstein Institutes For Medical Research Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
US12582819B2 (en) 2022-01-20 2026-03-24 Setpoint Medical Corporation Treatment of inflammatory disorders

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4342560A1 (de) * 1993-12-14 1995-06-22 Marbert Gmbh Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten
AU7528696A (en) * 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
US20040047828A1 (en) * 1998-08-01 2004-03-11 Merck Patent Gmbh Ectoin or ection derivatives and surfactants
US7048910B2 (en) 2000-09-07 2006-05-23 Merck Patent Gmbh Use of ectoine or ectoine derivatives for oral care
JP2005522457A (ja) * 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
DE10214257A1 (de) * 2002-03-28 2003-10-16 Merck Patent Gmbh Verwendung von kompatiblen Soluten zur Inhibierung der Freisetzung von Ceramiden
US20090275997A1 (en) * 2008-05-01 2009-11-05 Michael Allen Faltys Vagus nerve stimulation electrodes and methods of use
JP2013516497A (ja) * 2010-01-11 2013-05-13 ミスリィディオン，インク． 認知増強のための化合物と組成物、製造方法、および治療方法
WO2016073294A1 (en) * 2014-11-03 2016-05-12 William Beaumont Hospital Method for treating underactive bladder syndrome
JP2021066707A (ja) * 2019-10-25 2021-04-30 学校法人上智学院 環状化合物の製造方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710508A (en) * 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
EP0259621A2 (de) * 1986-09-08 1988-03-16 Novo Nordisk A/S Piperidinderivate, ihre Herstellung und ihre Verwendung
US4786648A (en) * 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
EP0296721A2 (de) * 1987-06-24 1988-12-28 H. Lundbeck A/S Heterocyclische Verbindungen
EP0384288A2 (de) * 1989-02-22 1990-08-29 Novo Nordisk A/S Piperidin-Derivate, ihre Herstellung und ihre Verwendung

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0259621A2 (de) * 1986-09-08 1988-03-16 Novo Nordisk A/S Piperidinderivate, ihre Herstellung und ihre Verwendung
US4710508A (en) * 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4786648A (en) * 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
EP0296721A2 (de) * 1987-06-24 1988-12-28 H. Lundbeck A/S Heterocyclische Verbindungen
EP0384288A2 (de) * 1989-02-22 1990-08-29 Novo Nordisk A/S Piperidin-Derivate, ihre Herstellung und ihre Verwendung

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
"Muscarinic Cholinergic Agonists & Antagonists of the 3-(3-Alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine Type, Synthesis & Structure-Activity Relationships", J. Med. Chem. 1991, 34, 687-692 by Sauerbert, et al.
"Novel Quinuclidine-Based Ligands for the Muscarinic Cholinergic Receptor", J. MEd. Chem. 1990, 33, 1128-1138.
"Routes to Functionalized Guandidines. The Synthesis of Guanidino Diesters", J. Org. Chem., vol. 38, No. 8, 1973.
"Synthesis & Biological Activity of 1,2,4-Oxadiazole Derivatives: Highly Potent & Efficacious Agonists for Cortical Muscarinic Receptors", J. Med, Chem. 1990, 33, 2690-2697.
"Synthesis", Jul. 1975, pp. 426-427.
"Tetrahydropyridyloxadiazoles: Semirigid Muscarinic Ligands", J. Med., Chem. 1991, 34, 1086-1094.
"The Synthesis & Pharamacology of Some 1,4,5,6-Tetrahydropyrimidines", Br. J. Pharmac. (1969), 37, 425-435.
Chem Abstract Registration No. 103(1):3305J. *
Chem Abstract Registration No. 117305 84 7. *
Chem Abstract Registration No. 117305-84-7.
Chem Abstract Registration No. 13519 32 9. *
Chem Abstract Registration No. 13519 33 0. *
Chem Abstract Registration No. 13519-32-9.
Chem Abstract Registration No. 13519-33-0.
Chem Abstract Registration No. 823 05 2. *
Chem Abstract Registration No. 823-05-2.
Chem Abstract Registration No. 96702 03 3. *
Chem Abstract Registration No. 96702-03-3.
Chem Abstracts 89, 1978, No. 89:109351d (Structure I) & 83, 1975, Abstract 178745y. *
European Journal of Pharmacology, 134 (1987) 61 67, Stimulation of Ganglionic Muscarinic M 1 Receptors by a Series of Tertiary Arecaidine & Isoarecaidine Esters in the Pithed Rat , p. 62. *
European Journal of Pharmacology, 134 (1987) 61-67, "Stimulation of Ganglionic Muscarinic M1 Receptors by a Series of Tertiary Arecaidine & Isoarecaidine Esters in the Pithed Rat", p. 62.
J. Med. Chem. 1990, 33, 2052 2059, colum 1, p. 2052 & column 2 p. 2053. *
J. Med. Chem. 1990, 33, 2052-2059, colum 1, p. 2052 & column 2 p. 2053.
Muscarinic Cholinergic Agonists & Antagonists of the 3 (3 Alkyl 1,2,4 oxadiazol 5 yl) 1,2,5,6 tetrahydropyridine Type, Synthesis & Structure Activity Relationships , J. Med. Chem. 1991, 34, 687 692 by Sauerbert, et al. *
Novel Quinuclidine Based Ligands for the Muscarinic Cholinergic Receptor , J. MEd. Chem. 1990, 33, 1128 1138. *
Proceedings of the British Pharmacological Society, 2nd 4th Apr., 1970 pp. 191 192. *
Proceedings of the British Pharmacological Society, 2nd-4th Apr., 1970 pp. 191-192.
Routes to Functionalized Guandidines. The Synthesis of Guanidino Diesters , J. Org. Chem., vol. 38, No. 8, 1973. *
STN international Registry No. 99767 88 1, p. 22, 1898 American Chemical Society Chem Abstracts, vol. 53, 5276E Yakugaku Zasshi, 78, 1166 70 (1958). *
STN international Registry No. 99767-88-1, p. 22, 1898 American Chemical Society Chem Abstracts, vol. 53, 5276E Yakugaku Zasshi, 78, 1166-70 (1958).
Synthesis & Biological Activity of 1,2,4 Oxadiazole Derivatives: Highly Potent & Efficacious Agonists for Cortical Muscarinic Receptors , J. Med, Chem. 1990, 33, 2690 2697. *
Synthesis , Jul. 1975, pp. 426 427. *
Tetrahydropyridyloxadiazoles: Semirigid Muscarinic Ligands , J. Med., Chem. 1991, 34, 1086 1094. *
The Synthesis & Pharamacology of Some 1,4,5,6 Tetrahydropyrimidines , Br. J. Pharmac. (1969), 37, 425 435. *

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559138A (en) * 1989-02-22 1996-09-24 Novo Nordisk A/S Method of Treating Glaucoma Using Oxadiazolyl or Thiadiazolyl Tetrahydropyridines
EP0897912A1 (de) * 1993-10-21 1999-02-24 G.D. Searle & Co. Amidinoderivate als NO-Synthetase-Inhibitoren
US6071906A (en) * 1993-10-21 2000-06-06 G. D. Searle & Co. Imidino piperidine derivatives useful as nitric oxide synthase inhibitors
EP0874625A4 (de) * 1996-01-22 2001-03-14 Lilly Co Eli Indanderivate für antipsychotische mittel
US5618818A (en) * 1996-03-20 1997-04-08 The University Of Toledo Muscarinic agonist compounds
US5726179A (en) * 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
WO1998046232A1 (en) * 1997-04-15 1998-10-22 The University Of Toledo Muscarinic agonists
US20030144285A1 (en) * 1998-03-31 2003-07-31 Mark Brann Compounds with activity on muscarinic receptors
US7485651B2 (en) 1998-03-31 2009-02-03 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US9987492B2 (en) 2000-05-23 2018-06-05 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US10166395B2 (en) 2000-05-23 2019-01-01 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US10561846B2 (en) 2000-05-23 2020-02-18 The Feinstein Institutes For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
KR100621192B1 (ko) 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US11344724B2 (en) 2004-12-27 2022-05-31 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US20090012101A1 (en) * 2005-12-27 2009-01-08 University Of Toledo Mucarinic Agonists and Methods of Use Thereof
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20090062874A1 (en) * 2007-08-27 2009-03-05 Tracey Kevin J Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US10835532B2 (en) 2008-05-15 2020-11-17 The University Of Toledo Muscarinic agonists as cognitive enhancers
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
WO2010102218A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9849286B2 (en) 2009-05-01 2017-12-26 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9174041B2 (en) 2009-06-09 2015-11-03 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US12251558B2 (en) 2009-06-09 2025-03-18 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US10716936B2 (en) 2009-06-09 2020-07-21 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US10220203B2 (en) 2009-06-09 2019-03-05 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9700716B2 (en) 2009-06-09 2017-07-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US10384068B2 (en) 2009-12-23 2019-08-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9993651B2 (en) 2009-12-23 2018-06-12 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US11110287B2 (en) 2009-12-23 2021-09-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US12290695B2 (en) 2009-12-23 2025-05-06 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8855767B2 (en) 2009-12-23 2014-10-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9162064B2 (en) 2009-12-23 2015-10-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9174972B2 (en) 2010-09-08 2015-11-03 Neurosolis, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9738633B2 (en) 2010-09-08 2017-08-22 Neurosolis, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9403806B1 (en) 2010-09-08 2016-08-02 Neurosolis, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
WO2012149524A1 (en) * 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
US12357826B2 (en) 2011-05-09 2025-07-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN102429909A (zh) * 2011-11-26 2012-05-02 济南环肽医药科技有限公司 一种治疗神经退行性疾病的药物
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US10449358B2 (en) 2012-03-26 2019-10-22 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11969253B2 (en) 2013-04-10 2024-04-30 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US12402826B2 (en) 2013-04-10 2025-09-02 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US12383741B2 (en) 2014-10-24 2025-08-12 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US11278718B2 (en) 2016-01-13 2022-03-22 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US11964150B2 (en) 2016-01-20 2024-04-23 Setpoint Medical Corporation Batteryless implantable microstimulators
US11547852B2 (en) 2016-01-20 2023-01-10 Setpoint Medical Corporation Control of vagal stimulation
US12296169B2 (en) 2016-01-20 2025-05-13 Setpoint Medical Corporation Batteryless implantable microstimulators
US12121726B2 (en) 2016-01-20 2024-10-22 Setpoint Medical Corporation Control of vagal stimulation
US12472368B2 (en) 2016-01-25 2025-11-18 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11383091B2 (en) 2016-01-25 2022-07-12 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11890471B2 (en) 2017-08-14 2024-02-06 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US12109405B2 (en) 2018-04-20 2024-10-08 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US12220579B2 (en) 2018-09-25 2025-02-11 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11857788B2 (en) 2018-09-25 2024-01-02 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12533531B2 (en) 2020-01-13 2026-01-27 The Feinstein Institutes For Medical Research Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12465768B2 (en) 2020-05-21 2025-11-11 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US12582819B2 (en) 2022-01-20 2026-03-24 Setpoint Medical Corporation Treatment of inflammatory disorders

Also Published As

Publication number Publication date
JPH06510287A (ja) 1994-11-17
CA2113424A1 (en) 1993-03-04
DE69230378T2 (de) 2000-04-06
JP2002047276A (ja) 2002-02-12
EP0630244A4 (de) 1994-04-07
EP0630244B1 (de) 1999-12-01
JP3411276B2 (ja) 2003-05-26
CA2113424C (en) 2003-11-11
ES2138977T3 (es) 2000-02-01
US5403845A (en) 1995-04-04
JP3519062B2 (ja) 2004-04-12
WO1993003726A1 (en) 1993-03-04
EP0630244A1 (de) 1994-12-28
ATE187070T1 (de) 1999-12-15
DE69230378D1 (de) 2000-01-05

Similar Documents

Publication Publication Date Title
US5175166A (en) Muscarinic agonists
JP3238414B2 (ja) トロパン―誘導体、その製造方法及びその使用方法
HUT65831A (en) Process for producing substituted 3-amino-quinuclidine derivatives and pharmaceutically acceptable salts
CZ283680B6 (cs) Nové azaheterocyklylmethyl-chromany
EP0544714B1 (de) Heterozyklische verbindungen, ihre herstellung und anwendung
IL109234A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
EP1049694B1 (de) Derivate von benzoxadiazol, benzothiadiazol, benzotriazol und chinoxalin
FI93211C (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 1,2,5,6-tetrahydropyridiinijohdannaisten valmistamiseksi
JP3351748B2 (ja) ２，３−ジ置換−（５，６）−ヘテロアリール縮合−ピリミジン−４−オンの新規なアトロプ異性体
HUT54151A (en) Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds
CN101855223A (zh) 新的1,4-二氮杂-二环[3.2.2]壬基嘧啶衍生物及它们的医药应用
CA2116117A1 (en) Benzisoxazole compound and use thereof
HUT71132A (en) Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing
US4897399A (en) Heterotertracyclic lactam derivatives, pharmaceutical compositions, and method of treating impaired memory and learning
US6602865B1 (en) Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
US4305943A (en) 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics
CA2350560C (en) Novel type condensed pyridazinone compounds
US5733908A (en) Tetracyclic 1,4-oxazine compounds
US5109006A (en) Certain pharmaceutically active 6H-imidazo[1,2-a]pyridine-5-ones
US5015645A (en) Tetracyclic pyrrole lactam derivatives
Cliffe et al. Rearrangements of pyrimido-and diazepino-[1, 2-a] indoles: syntheses of 1, 5-benzodiazocines and 1, 6-benzodiazonines
JP4845139B2 (ja) エナンチオマー的に純粋なヘキサヒドロピロロシクロペンタピリジン誘導体
JPH07215954A (ja) 新規ベンゾチアジアジン化合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF TOLEDO, THE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:DURANT, GRAHAM J.;REEL/FRAME:005923/0191

Effective date: 19911015

Owner name: UNIVERSITY OF TOLEDO, THE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:MESSER, WILLIAM S., JR.;REEL/FRAME:005923/0197

Effective date: 19911015

Owner name: UNIVERSITY OF TOLEDO, THE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:DUNBAR, PHILIP G.;REEL/FRAME:005923/0194

Effective date: 19911016

Owner name: UNIVERSITY OF TOLEDO, THE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:HOSS, WAYNE P.;REEL/FRAME:005923/0200

Effective date: 19911015

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment

Year of fee payment: 11